Clinical Trial Update: A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy [Phase 3]

View source ↗

Summary

A Phase 3 global study evaluating Volrustomig (MEDI5752) in participants with unresected locally advanced head and neck squamous cell carcinoma after definitive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Volrustomig

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING